SAN DIEGO--(BUSINESS WIRE)--The common amino-acid methionine, present in all proteins, is a culprit in the aging process as well as in cancer. It is well known that dietary restriction of methionine can greatly extend a healthy life-span, and even reverse aspects of aging, as well as eradicate cancer in animal models. However, methionine-restricted diets cause unacceptable weight loss in humans because the diet requires protein restriction.
Solution to this problem of methionine restriction is AntiCancer Inc’s new development of an oral formulation of the enzyme methioninase (METase) which reduces methionine in the blood by 80% within 3 hours and does not cause weight loss when taken chronically. Oral administration of METase was highly effective in regressing human-patient cancer implanted in mouse models. Most exciting, normal healthy people will be able to take oral METase to hopefully lower methionine in their bodies and extend their healthy life-span while becoming more youthful. METase is produced very economically and at large scale by a fermentation process.
Dr. Qinghong Han, co-inventor of oral METase, says “I am already taking oral METase with no side effects and I am hoping to extend my healthy life-span to beyond the world record.” Project leader Dr. Yuying Tan said, “Our goal is the best selling drug ever, after regulatory approval, for oral METase to be taken for an extended life-span by healthy people, as well as cancer patients. Everyone wants to live longer and feel younger and will want oral METase.” “Oral METase is a pharma-company’s dream, it extends the life-span needed to take the drug,” said AntiCancer founder, Robert M. Hoffman, a researcher for more than half a century.
AntiCancer’s new results on oral METase for cancer will be published in an upcoming issue of the journal Cell Cycle.
About AntiCancer Inc.
AntiCancer Inc., founded in 1984 and based in San Diego, with offices and laboratories in Seoul, Beijing, Nanjing and Tokyo, markets the leading mouse models for cancer research, drug development and drug discovery as a service to pharma, biotech and academia. AntiCancer is also developing its proprietary tumor-targeting bacteria as a general therapeutic for cancer. In addition, AntiCancer is developing pluripotent stem cells from the hair follicle for regenerative medicine. AntiCancer also markets unique recombinant-enzyme-based diagnostics.